Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Cyclin O controls entry into the cell-cycle variant required for multiciliated cell differentiation

  • Khoury Damaa, Michella
  • Gil Gómez, Gabriel
  • Meunier, Alice
Multiciliated cells (MCCs) ensure fluid circulation in various organs. Their differentiation is marked by the amplification of cilia-nucleating centrioles, driven by a genuine cell-cycle variant, which is characterized by wave-like expression of canonical and non-canonical cyclins such as Cyclin O (CCNO). Patients with CCNO mutations exhibit a subtype of primary ciliary dyskinesia called reduced generation of motile cilia (RGMC). Here, we show that Ccno is activated at the crossroads of the onset of MCC differentiation, the entry into the MCC cell-cycle variant, and the activation of the centriole biogenesis program. Its absence blocks the G1/S-like transition of the cell-cycle variant, interrupts the centriologenesis transcription program, and compromises the production of centrioles and cilia in mouse brain and human respiratory MCCs. Altogether, our study identifies CCNO as a core regulator of entry into the MCC cell-cycle variant and the interruption of this variant as one etiology of RGMC., This work is supported by funding to A.M. from the ANR (ANR-19-CE13-0027) and Q-life Program. The Spassky lab is also funded by Inserm, the CNRS, the École Normale Supérieure, the ANR (ANR-20-CE45-0019, ANR-21-CE16-0016, ANR-22-CE16-0011), the European Research Council (ERC grant agreement 647466), and the Fondation pour la Recherche Médicale (FRM, EQU 202103012767). The Roy lab is supported by the Agency for Science, Technology and Research (A∗STAR) and a National Medical Research Council of Singapore grant (OFIRG19nov-0037). R.K. is supported by the Institut Pasteur, CNRS, and the European Research Council (ERC grant agreement 771813); J.S. is funded by the Association pour la Recherche sur le Cancer; M.K.D. is funded by the FRM; A.-R.B. is funded by La Ligue Contre Le Cancer; C.T.J. was supported by an A∗STAR Research Attachment Program (ARAP) fellowship; and S.J.A. is supported by the German Research Foundation through a Heisenberg Professorship (AR 732/3-1), project P7 of SFB 1453 (project ID 431984000) and Germany's Excellence Strategy (CIBSS – EXC-2189 – Project ID 390939984). This work was performed with support from the National Infrastructure France Génomique (Commissariat aux Grands Investissements, ANR-10-INBS-09-03, ANR-10-INBS-09-02), the 3IA Côte d’Azur (ANR-19-P3IA-0002), European Union’s H2020 Research and Innovation Program under grant agreement no. 874656 (discovAIR), and Conseil départemental 06 (2016-294DGADSH-CV).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cyclin O controls entry into the cell-cycle variant required for multiciliated cell differentiation

  • Khoury Damaa, Michella
  • Gil Gómez, Gabriel
  • Meunier, Alice
Multiciliated cells (MCCs) ensure fluid circulation in various organs. Their differentiation is marked by the amplification of cilia-nucleating centrioles, driven by a genuine cell-cycle variant, which is characterized by wave-like expression of canonical and non-canonical cyclins such as Cyclin O (CCNO). Patients with CCNO mutations exhibit a subtype of primary ciliary dyskinesia called reduced generation of motile cilia (RGMC). Here, we show that Ccno is activated at the crossroads of the onset of MCC differentiation, the entry into the MCC cell-cycle variant, and the activation of the centriole biogenesis program. Its absence blocks the G1/S-like transition of the cell-cycle variant, interrupts the centriologenesis transcription program, and compromises the production of centrioles and cilia in mouse brain and human respiratory MCCs. Altogether, our study identifies CCNO as a core regulator of entry into the MCC cell-cycle variant and the interruption of this variant as one etiology of RGMC., This work is supported by funding to A.M. from the ANR (ANR-19-CE13-0027) and Q-life Program. The Spassky lab is also funded by Inserm, the CNRS, the École Normale Supérieure, the ANR (ANR-20-CE45-0019, ANR-21-CE16-0016, ANR-22-CE16-0011), the European Research Council (ERC grant agreement 647466), and the Fondation pour la Recherche Médicale (FRM, EQU 202103012767). The Roy lab is supported by the Agency for Science, Technology and Research (A∗STAR) and a National Medical Research Council of Singapore grant (OFIRG19nov-0037). R.K. is supported by the Institut Pasteur, CNRS, and the European Research Council (ERC grant agreement 771813); J.S. is funded by the Association pour la Recherche sur le Cancer; M.K.D. is funded by the FRM; A.-R.B. is funded by La Ligue Contre Le Cancer; C.T.J. was supported by an A∗STAR Research Attachment Program (ARAP) fellowship; and S.J.A. is supported by the German Research Foundation through a Heisenberg Professorship (AR 732/3-1), project P7 of SFB 1453 (project ID 431984000) and Germany's Excellence Strategy (CIBSS – EXC-2189 – Project ID 390939984). This work was performed with support from the National Infrastructure France Génomique (Commissariat aux Grands Investissements, ANR-10-INBS-09-03, ANR-10-INBS-09-02), the 3IA Côte d’Azur (ANR-19-P3IA-0002), European Union’s H2020 Research and Innovation Program under grant agreement no. 874656 (discovAIR), and Conseil départemental 06 (2016-294DGADSH-CV).